Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide for Peripheral T Cell Lymphoma: The Importance of Graft Source

Sterling, Cole; Tsai, Hua‐Ling; Yarkony, Kathryn; Fuchs, Ephraim J.; Swinnen, Lode J.; Paul, Suman; Bolaños-Meade, Javier; Luznik, Leo; Imus, Philip; Ali, Syed Abbas; Jain, Tania; Ambinder, Alexander J.; DeZern, Amy E.; Huff, Carol Ann; Gocke, Christian B.; Varadhan, Ravi; Wagner‐Johnston, Nina D.; Jones, Richard J.; Ambinder, Richard F.

doi:10.1016/j.jtct.2022.12.009

Cited by 3 publications

(1 citation statement)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…15 Like we previously showed in other high-risk diseases, higher TBI dose and the use of PB allografts may result in longer survival after alloHCT. 9,10 Given the poor outcome with a standard alloHCT in patients with TP53-CK, novel approach-es focused either on improving the immune effect of the graft or targeted maintenance therapies will be critical to improving outcomes.…”

Section: Letter To the Editormentioning

confidence: 99%

Outcome heterogeneity of <i>TP53</i>-mutated myeloid neoplasms and the role of allogeneic hematopoietic cell transplantation

Pasca,

Haldar,

Ambinder

et al. 2023

haematol

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Letter To the Editormentioning

confidence: 99%

Outcome heterogeneity of <i>TP53</i>-mutated myeloid neoplasms and the role of allogeneic hematopoietic cell transplantation

Pasca,

Haldar,

Ambinder

et al. 2023

haematol

Self Cite

View full text Add to dashboard Cite

show abstract

Cyclophosphamide/fludarabine/mycophenolate-mofetil

2023

Reactions Weekly

View full text Add to dashboard Cite

Recipient clonal hematopoiesis in allogeneic bone marrow transplantation for lymphoid malignancies

Imus,

Pasca,

Tsai

et al. 2024

Blood Advances

View full text Add to dashboard Cite

Allogeneic blood and marrow transplantation (alloBMT) is increasingly being used in older patients with blood cancer. Aging is associated with an increasing incidence of clonal hematopoiesis (CH). Although the effects of donor CH on alloBMT has been reported, the impact of recipient CH on alloBMT outcomes is unknown. In this retrospective study, alloBMT recipients age 60 and older with lymphoid malignancies were included. Among 97 consecutive patients who received alloBMT between 2017 and 2022, CH was detected in 60 (62%; 95% CI 51-72%). CH was found in 45% (95% CI 28-64%) of patients aged 60-64, 64% (95% CI 44-81%) of patients aged 65-69, and 73% (95% CI 59-87%) in those above 70. Pretransplant CH was associated with worse survival after alloBMT: 3-year overall survival (OS) was 78% (95% CI 65-94%) for patients without CH versus 47% (95% CI 35-63%) for those with CH, [unadjusted HR 3.1 (95%CI 1.4-6.8; P<0.001)]. Non-relapse mortality (NRM) was higher in patients with CH; cumulative incidence of NRM at one-year was 11% (95% CI 1-22%) versus 35% (95% CI 23-48%), [HR 3.4 (95% CI 1.4-8.5), p=0.009]. Among CH patients, worse OS and NRM was associated with CH burden and number of mutations. Recipient CH had no effect on relapse. In conclusion, older patients with CH experience worse outcomes after alloBMT, almost exclusively attributable to increased NRM. CH is a strong, independent predictor of outcomes. Novel strategies to ameliorate the adverse impacts of patient CH on transplant outcomes are being evaluated.

show abstract

Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide for Peripheral T Cell Lymphoma: The Importance of Graft Source

Cited by 3 publications

References 43 publications

Outcome heterogeneity of <i>TP53</i>-mutated myeloid neoplasms and the role of allogeneic hematopoietic cell transplantation

Outcome heterogeneity of <i>TP53</i>-mutated myeloid neoplasms and the role of allogeneic hematopoietic cell transplantation

Cyclophosphamide/fludarabine/mycophenolate-mofetil

Recipient clonal hematopoiesis in allogeneic bone marrow transplantation for lymphoid malignancies

Contact Info

Product

Resources

About